Radius Health (RDUS) : Traders are bullish on Radius Health (RDUS) as it has outperformed the S&P 500 by a wide margin of 30.03% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 16.16%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 16.66% in the last 1 week, and is up 33.26% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Radius Health (NASDAQ:RDUS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $50.99 and $50.09 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $55.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $54.97, notching a gain of 8.74% for the day. The total traded volume was 1,183,028 . The stock had closed at $50.55 on the previous day.
The stock has recorded a 20-day Moving Average of 24.7% and the 50-Day Moving Average is 38.52%. Radius Health, Inc. is up 77.72% in the last 3-month period. Year-to-Date the stock performance stands at -10.68%.
Radius Health (RDUS) : 5 Wall Street analysts covering Radius Health (RDUS) believe that the average level the stock could reach for the short term is $48.8. The maximum price target given is $70 and the minimum target for short term is around $24, hence the standard deviation is calculated at $18.21.
Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.